# Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

> **NCT04550481** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Northwestern University** · enrollment: 45 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Nonalcoholic Steatohepatitis

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Lisinopril
- **PROCEDURE:** Liver Ultrasonographic Elastography
- **PROCEDURE:** Magnetic Resonance Elastography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Proton Density Fat Fraction
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04550481
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-11
- **Primary completion:** 2025-08-08
- **Final completion:** 2026-09-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04550481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04550481, "Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04550481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*